img

Global Primary Immunodeficiency Therapeutic Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Primary Immunodeficiency Therapeutic Market Insights, Forecast to 2034

Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.
Market Analysis and InsightsGlobal Primary Immunodeficiency Therapeutic Market
Global Primary Immunodeficiency Therapeutic market is expected to reach to US$ 483 million in 2024, with a positive growth of %, compared with US$ 459 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Primary Immunodeficiency Therapeutic industry is evaluated to reach US$ 669.8 million in 2029. The CAGR will be 5.6% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Primary Immunodeficiency Therapeutic market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Primary Immunodeficiency Therapeutic market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals
Segment by Type
Immunoglobulin Replacement Therapy
Stem Cell or Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others

Segment by Application


Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Primary Immunodeficiency Therapeutic introduction, etc. Primary Immunodeficiency Therapeutic Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Primary Immunodeficiency Therapeutic
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Immunoglobulin Replacement Therapy
1.2.3 Stem Cell or Bone Marrow Transplantation
1.2.4 Antibiotic Therapy
1.2.5 Gene Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Antibody Deficiency
1.3.3 Cellular Immunodeficiency
1.3.4 Innate Immune Disorders
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Immunodeficiency Therapeutic Market Perspective (2018-2029)
2.2 Global Primary Immunodeficiency Therapeutic Growth Trends by Region
2.2.1 Primary Immunodeficiency Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Immunodeficiency Therapeutic Historic Market Size by Region (2018-2024)
2.2.3 Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Primary Immunodeficiency Therapeutic Market Dynamics
2.3.1 Primary Immunodeficiency Therapeutic Industry Trends
2.3.2 Primary Immunodeficiency Therapeutic Market Drivers
2.3.3 Primary Immunodeficiency Therapeutic Market Challenges
2.3.4 Primary Immunodeficiency Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Primary Immunodeficiency Therapeutic by Players
3.1.1 Global Primary Immunodeficiency Therapeutic Revenue by Players (2018-2024)
3.1.2 Global Primary Immunodeficiency Therapeutic Revenue Market Share by Players (2018-2024)
3.2 Global Primary Immunodeficiency Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Primary Immunodeficiency Therapeutic, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio
3.4.1 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Immunodeficiency Therapeutic Revenue in 2022
3.5 Global Key Players of Primary Immunodeficiency Therapeutic Head office and Area Served
3.6 Global Key Players of Primary Immunodeficiency Therapeutic, Product and Application
3.7 Global Key Players of Primary Immunodeficiency Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Immunodeficiency Therapeutic Breakdown Data by Type
4.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Type (2018-2024)
4.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2024-2029)
5 Primary Immunodeficiency Therapeutic Breakdown Data by Application
5.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Application (2018-2024)
5.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Immunodeficiency Therapeutic Market Size (2018-2029)
6.2 North America Primary Immunodeficiency Therapeutic Market Size by Type
6.2.1 North America Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024)
6.2.2 North America Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029)
6.2.3 North America Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
6.3 North America Primary Immunodeficiency Therapeutic Market Size by Application
6.3.1 North America Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024)
6.3.2 North America Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029)
6.3.3 North America Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
6.4 North America Primary Immunodeficiency Therapeutic Market Size by Country
6.4.1 North America Primary Immunodeficiency Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
6.4.3 North America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Primary Immunodeficiency Therapeutic Market Size (2018-2029)
7.2 Europe Primary Immunodeficiency Therapeutic Market Size by Type
7.2.1 Europe Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024)
7.2.2 Europe Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029)
7.2.3 Europe Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
7.3 Europe Primary Immunodeficiency Therapeutic Market Size by Application
7.3.1 Europe Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024)
7.3.2 Europe Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029)
7.3.3 Europe Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
7.4 Europe Primary Immunodeficiency Therapeutic Market Size by Country
7.4.1 Europe Primary Immunodeficiency Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
7.4.3 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Primary Immunodeficiency Therapeutic Market Size (2018-2029)
8.2 China Primary Immunodeficiency Therapeutic Market Size by Type
8.2.1 China Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024)
8.2.2 China Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029)
8.2.3 China Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
8.3 China Primary Immunodeficiency Therapeutic Market Size by Application
8.3.1 China Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024)
8.3.2 China Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029)
8.3.3 China Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Primary Immunodeficiency Therapeutic Market Size (2018-2029)
9.2 Asia Primary Immunodeficiency Therapeutic Market Size by Type
9.2.1 Asia Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024)
9.2.2 Asia Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029)
9.2.3 Asia Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
9.3 Asia Primary Immunodeficiency Therapeutic Market Size by Application
9.3.1 Asia Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024)
9.3.2 Asia Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029)
9.3.3 Asia Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
9.4 Asia Primary Immunodeficiency Therapeutic Market Size by Region
9.4.1 Asia Primary Immunodeficiency Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024)
9.4.3 Asia Primary Immunodeficiency Therapeutic Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Type
10.2.1 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Application
10.3.1 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Country
10.4.1 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Baxter International
11.1.1 Baxter International Company Details
11.1.2 Baxter International Business Overview
11.1.3 Baxter International Primary Immunodeficiency Therapeutic Introduction
11.1.4 Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.1.5 Baxter International Recent Developments
11.2 Takeda Pharmaceutical
11.2.1 Takeda Pharmaceutical Company Details
11.2.2 Takeda Pharmaceutical Business Overview
11.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Introduction
11.2.4 Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.2.5 Takeda Pharmaceutical Recent Developments
11.3 CSL Limited
11.3.1 CSL Limited Company Details
11.3.2 CSL Limited Business Overview
11.3.3 CSL Limited Primary Immunodeficiency Therapeutic Introduction
11.3.4 CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.3.5 CSL Limited Recent Developments
11.4 Octapharma
11.4.1 Octapharma Company Details
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Primary Immunodeficiency Therapeutic Introduction
11.4.4 Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.4.5 Octapharma Recent Developments
11.5 Kedrion Biopharma
11.5.1 Kedrion Biopharma Company Details
11.5.2 Kedrion Biopharma Business Overview
11.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Introduction
11.5.4 Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.5.5 Kedrion Biopharma Recent Developments
11.6 Bio Products Laboratory
11.6.1 Bio Products Laboratory Company Details
11.6.2 Bio Products Laboratory Business Overview
11.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Introduction
11.6.4 Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.6.5 Bio Products Laboratory Recent Developments
11.7 LFB group
11.7.1 LFB group Company Details
11.7.2 LFB group Business Overview
11.7.3 LFB group Primary Immunodeficiency Therapeutic Introduction
11.7.4 LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.7.5 LFB group Recent Developments
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Primary Immunodeficiency Therapeutic Introduction
11.8.4 Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.8.5 Grifols Recent Developments
11.9 Lupin Pharmaceuticals
11.9.1 Lupin Pharmaceuticals Company Details
11.9.2 Lupin Pharmaceuticals Business Overview
11.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Introduction
11.9.4 Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.9.5 Lupin Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Immunoglobulin Replacement Therapy
Table 3. Key Players of Stem Cell or Bone Marrow Transplantation
Table 4. Key Players of Antibiotic Therapy
Table 5. Key Players of Gene Therapy
Table 6. Key Players of Others
Table 7. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Primary Immunodeficiency Therapeutic Market Share by Region (2018-2024)
Table 11. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Primary Immunodeficiency Therapeutic Market Share by Region (2024-2029)
Table 13. Primary Immunodeficiency Therapeutic Market Trends
Table 14. Primary Immunodeficiency Therapeutic Market Drivers
Table 15. Primary Immunodeficiency Therapeutic Market Challenges
Table 16. Primary Immunodeficiency Therapeutic Market Restraints
Table 17. Global Primary Immunodeficiency Therapeutic Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Primary Immunodeficiency Therapeutic Revenue Share by Players (2018-2024)
Table 19. Global Top Primary Immunodeficiency Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2022)
Table 20. Global Primary Immunodeficiency Therapeutic Industry Ranking 2021 VS 2022 VS 2024
Table 21. Global 5 Largest Players Market Share by Primary Immunodeficiency Therapeutic Revenue (CR5 and HHI) & (2018-2024)
Table 22. Global Key Players of Primary Immunodeficiency Therapeutic, Headquarters and Area Served
Table 23. Global Key Players of Primary Immunodeficiency Therapeutic, Product and Application
Table 24. Global Key Players of Primary Immunodeficiency Therapeutic, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2024)
Table 28. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2024-2029)
Table 30. Global Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Primary Immunodeficiency Therapeutic Revenue Share by Application (2018-2024)
Table 32. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Primary Immunodeficiency Therapeutic Revenue Share by Application (2024-2029)
Table 34. North America Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 35. North America Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 37. North America Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Primary Immunodeficiency Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 40. North America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 42. Europe Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 44. Europe Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Primary Immunodeficiency Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 47. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 49. China Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 51. China Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 53. Asia Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 55. Asia Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Primary Immunodeficiency Therapeutic Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 58. Asia Primary Immunodeficiency Therapeutic Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 66. Baxter International Company Details
Table 67. Baxter International Business Overview
Table 68. Baxter International Primary Immunodeficiency Therapeutic Product
Table 69. Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 70. Baxter International Recent Developments
Table 71. Takeda Pharmaceutical Company Details
Table 72. Takeda Pharmaceutical Business Overview
Table 73. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product
Table 74. Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 75. Takeda Pharmaceutical Recent Developments
Table 76. CSL Limited Company Details
Table 77. CSL Limited Business Overview
Table 78. CSL Limited Primary Immunodeficiency Therapeutic Product
Table 79. CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 80. CSL Limited Recent Developments
Table 81. Octapharma Company Details
Table 82. Octapharma Business Overview
Table 83. Octapharma Primary Immunodeficiency Therapeutic Product
Table 84. Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 85. Octapharma Recent Developments
Table 86. Kedrion Biopharma Company Details
Table 87. Kedrion Biopharma Business Overview
Table 88. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product
Table 89. Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 90. Kedrion Biopharma Recent Developments
Table 91. Bio Products Laboratory Company Details
Table 92. Bio Products Laboratory Business Overview
Table 93. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product
Table 94. Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 95. Bio Products Laboratory Recent Developments
Table 96. LFB group Company Details
Table 97. LFB group Business Overview
Table 98. LFB group Primary Immunodeficiency Therapeutic Product
Table 99. LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 100. LFB group Recent Developments
Table 101. Grifols Company Details
Table 102. Grifols Business Overview
Table 103. Grifols Primary Immunodeficiency Therapeutic Product
Table 104. Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 105. Grifols Recent Developments
Table 106. Lupin Pharmaceuticals Company Details
Table 107. Lupin Pharmaceuticals Business Overview
Table 108. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product
Table 109. Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 110. Lupin Pharmaceuticals Recent Developments
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Primary Immunodeficiency Therapeutic Market Share by Type: 2022 VS 2029
Figure 3. Immunoglobulin Replacement Therapy Features
Figure 4. Stem Cell or Bone Marrow Transplantation Features
Figure 5. Antibiotic Therapy Features
Figure 6. Gene Therapy Features
Figure 7. Others Features
Figure 8. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Primary Immunodeficiency Therapeutic Market Share by Application: 2022 VS 2029
Figure 10. Antibody Deficiency Case Studies
Figure 11. Cellular Immunodeficiency Case Studies
Figure 12. Innate Immune Disorders Case Studies
Figure 13. Others Case Studies
Figure 14. Primary Immunodeficiency Therapeutic Report Years Considered
Figure 15. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Primary Immunodeficiency Therapeutic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Primary Immunodeficiency Therapeutic Market Share by Region: 2022 VS 2029
Figure 18. Global Primary Immunodeficiency Therapeutic Market Share by Players in 2022
Figure 19. Global Top Primary Immunodeficiency Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2022
Figure 21. North America Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
Figure 23. North America Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
Figure 24. North America Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 25. United States Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Primary Immunodeficiency Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 28. Europe Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
Figure 29. Europe Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
Figure 30. Europe Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 31. Germany Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. France Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. U.K. Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Italy Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Russia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Nordic Countries Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. China Primary Immunodeficiency Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 38. China Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
Figure 39. China Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
Figure 40. Asia Primary Immunodeficiency Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 41. Asia Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
Figure 42. Asia Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
Figure 43. Asia Primary Immunodeficiency Therapeutic Market Share by Region (2018-2029)
Figure 44. Japan Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. South Korea Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. China Taiwan Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Southeast Asia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. India Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Australia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 51. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Share by Type (2018-2029)
Figure 52. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Share by Application (2018-2029)
Figure 53. Middle East, Africa, and Latin America Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 54. Brazil Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Mexico Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Turkey Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Israel Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. GCC Countries Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. Baxter International Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 61. Takeda Pharmaceutical Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 62. CSL Limited Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 63. Octapharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 64. Kedrion Biopharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 65. Bio Products Laboratory Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 66. LFB group Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 67. Grifols Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 68. Lupin Pharmaceuticals Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries